TRIO-US Streamline Elegant STML-ELA-0422

A Phase 3 Study, Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-Positive, Estrogen Receptor-Positive, HER2-Negative, Early breast Cancer with High Risk of Recurrence